

Howard P Gurney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7284743/publications.pdf>

Version: 2024-02-01

219
papers

23,311
citations

47409

49
h-index

9865

146
g-index

222
all docs

222
docs citations

222
times ranked

20766
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of retroperitoneal lymph node dissection for testicular cancer by a high volume surgeon from Australia: a case for centralisation. ANZ Journal of Surgery, 2022, 92, 1044-1049.	0.3	4
2	¹⁸ F-DCFPyL PET/CT in Metastatic Renal Cell Carcinoma. Journal of Nuclear Medicine Technology, 2022, 50, 282-285.	0.4	0
3	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. European Urology, 2022, 81, 266-271.	0.9	33
4	Patient Preference or Indifference: Learning from the CABADOC Study. European Urology, 2022, 81, 241-242.	0.9	0
5	Phase 3 study of first-line treatment with pembrolizumab + belzutifan + lenvatinib or pembrolizumab/quavonlimab + lenvatinib versus pembrolizumab + lenvatinib for advanced renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2022, 40, TPS399-TPS399.	0.8	5
6	A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2022, 40, 95-95.	0.8	4
7	Post hoc analysis of the efficacy of pembrolizumab retreatment after progression of advanced urothelial carcinoma (UC) in KEYNOTE-045 and KEYNOTE-052.. Journal of Clinical Oncology, 2022, 40, 512-512.	0.8	2
8	Insulin-like growth factor role in determining the anti-cancer effect of metformin: RCT in prostate cancer patients. Endocrine Connections, 2022, 11, .	0.8	3
9	Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region. Asia-Pacific Journal of Clinical Oncology, 2022, 18, .	0.7	5
10	Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. Cancer, 2022, 128, 2085-2097.	2.0	103
11	Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study. European Urology, 2022, 82, 22-30.	0.9	34
12	Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. Future Oncology, 2022, 18, 2361-2371.	1.1	4
13	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. Clinical Cancer Research, 2022, 28, 2050-2060.	3.2	21
14	Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 888-898.	5.1	114
15	KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pretreated patients with metastatic castration-resistant prostate cancer (mCRPC) New data after an additional 1 year of follow-up.. Journal of Clinical Oncology, 2021, 39, 10-10.	0.8	10
16	UNISON - nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma (ANZUP 1602): Part 1 Nivolumab monotherapy.. Journal of Clinical Oncology, 2021, 39, 325-325.	0.8	3
17	High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial. BMJ Open, 2021, 11, e044055.	0.8	3
18	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine, 2021, 384, 1289-1300.	13.9	956

#	ARTICLE	IF	CITATIONS
19	Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms.. Journal of Clinical Oncology, 2021, 39, 4562-4562.	0.8	2
20	Pembrolizumab (pembro) versus investigator's choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.. Journal of Clinical Oncology, 2021, 39, 4532-4532.	0.8	32
21	Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.. Journal of Clinical Oncology, 2021, 39, 4553-4553.	0.8	16
22	Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.. Journal of Clinical Oncology, 2021, 39, 4525-4525.	0.8	3
23	Ipilimumab + nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2021, 39, 4565-4565.	0.8	1
24	Patterns of care and outcomes of men with germ cell tumors in a high-volume Australian center. Asia-Pacific Journal of Clinical Oncology, 2021, , .	0.7	0
25	Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. New England Journal of Medicine, 2021, 385, 683-694.	13.9	394
26	Radioimmunotherapy for solid tumors: spotlight on Glypican-1 as a radioimmunotherapy target. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110229.	1.4	3
27	Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?. European Journal of Hospital Pharmacy, 2021, 28, 83-87.	0.5	1
28	Thyroid gland metastasis from renal cell carcinoma: a case series and literature review. ANZ Journal of Surgery, 2021, 91, 708-715.	0.3	7
29	Safety and tolerability of Miltuximab - a first in human study in patients with advanced solid cancers. Asia Oceania Journal of Nuclear Medicine and Biology, 2021, 9, 86-100.	0.1	2
30	KEYNOTE-365 cohort C: pembrolizumab + enzalutamide in patients with abiraterone acetate-pretreated metastatic castration-resistant prostate cancer (mCRPC) data after minimum of 22 months of follow-up. , 2021, 9, A374-A374.		2
31	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
32	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer, 2020, 126, 4156-4167.	2.0	201
33	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open, 2020, 5, e001079.	2.0	343
34	Science and art of anticancer drug dosing: nine steps to personalised therapy. Internal Medicine Journal, 2020, 50, 992-996.	0.5	0
35	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, The, 2020, 21, 1574-1588.	5.1	324
36	711P Nivolumab + ipilimumab (N+I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy. Annals of Oncology, 2020, 31, S559-S560.	0.6	21

#	ARTICLE	IF	CITATIONS
37	625P Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update. <i>Annals of Oncology</i> , 2020, 31, S516-S517.	0.6	4
38	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2020, 383, 1218-1230.	13.9	802
39	Nuances to precision dosing strategies of targeted cancer medicines. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00625.	1.1	9
40	Cardiovascular Toxicity of Targeted Therapies for Cancer: An Overview of Systematic Reviews. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa076.	1.4	23
41	704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100. <i>Annals of Oncology</i> , 2020, 31, S555-S556.	0.6	12
42	744P Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC). <i>Annals of Oncology</i> , 2020, 31, S577-S578.	0.6	0
43	766P Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study. <i>Annals of Oncology</i> , 2020, 31, S591.	0.6	1
44	621P Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update. <i>Annals of Oncology</i> , 2020, 31, S513-S514.	0.6	5
45	Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio. <i>Breast</i> , 2020, 54, 229-234.	0.9	3
46	Evaluating bioanalytical capabilities of paper spray ionization for abiraterone drug quantification in patient plasma. <i>Journal of Mass Spectrometry</i> , 2020, 55, e4584.	0.7	6
47	Melphalan exposure and outcome in obese and non-obese adults with myeloma. A study of pharmacokinetics and pharmacodynamics. <i>Bone Marrow Transplantation</i> , 2020, 55, 1862-1864.	1.3	3
48	A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2020, 31, 257-265.	0.6	12
49	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2506-2514.	3.2	20
50	Androgen deprivation in prostate cancer: benefits of home-based resistance training. <i>Sports Medicine - Open</i> , 2020, 6, 59.	1.3	9
51	The Adverse Effects of Androgen Deprivation Therapy in Prostate Cancer and the Benefits and Potential Anti-oncogenic Mechanisms of Progressive Resistance Training. <i>Sports Medicine - Open</i> , 2020, 6, 13.	1.3	18
52	Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5544-5544.	0.8	14
53	Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, LBA1-LBA1.	0.8	64
54	KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 100-100.	0.8	34

#	ARTICLE	IF	CITATIONS
55	KEYNOTE-365 cohort C updated results: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 102-102.	0.8	9
56	KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 103-103.	0.8	10
57	Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B efficacy, safety and, biomarker results.. Journal of Clinical Oncology, 2020, 38, 5550-5550.	0.8	5
58	Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.. Journal of Clinical Oncology, 2020, 38, 5545-5545.	0.8	4
59	Atezolizumab (atezo) therapy for locally advanced/metastatic urinary tract carcinoma (mUTC) in patients (pts) with poor performance status (PS): Analysis of the prospective global SAUL study.. Journal of Clinical Oncology, 2020, 38, 5035-5035.	0.8	0
60	Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma. Kidney Cancer, 2020, 4, 185-195.	0.2	0
61	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1370-1385.	5.1	594
62	Bioanalytical evaluation of dried plasma spots for monitoring of abiraterone and $\hat{\dagger}$ (4)-abiraterone from cancer patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1126-1127, 121741.	1.2	9
63	Clinical concepts for cabazitaxel in the management of metastatic castration-resistant prostate cancer. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 288-295.	0.7	7
64	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet, The, 2019, 393, 2404-2415.	6.3	778
65	Tamoxifen-induced severe hot flashes and endoxifen levels: is dose reduction a safe and effective strategy?. Breast, 2019, 46, 52-57.	0.9	9
66	Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 139-146.	1.1	10
67	Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Annals of Oncology, 2019, 30, 970-976.	0.6	329
68	Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2019, 380, 1103-1115.	13.9	1,824
69	Abstract CT162: Pembrolizumab monotherapy for the adjuvant treatment of renal cell carcinoma post-nephrectomy: Randomized, double-blind, Phase III KEYNOTE-564 study. , 2019, , .		1
70	Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort C of the phase 1b/2 KEYNOTE-365 study.. Journal of Clinical Oncology, 2019, 37, 5010-5010.	0.8	3
71	Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.. Journal of Clinical Oncology, 2019, 37, 5027-5027.	0.8	7
72	Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.. Journal of Clinical Oncology, 2019, 37, 5029-5029.	0.8	2

#	ARTICLE	IF	CITATIONS
73	Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 145-145.	0.8	43
74	Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 170-170.	0.8	3
75	Keynote-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 171-171.	0.8	14
76	Clinical validation of circulating cytokines as markers of prognosis and response to docetaxel in men with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2019, 37, 230-230.	0.8	2
77	Outcomes of the miltuximab first in human trial and proposed study design for a phase I trial ⁸⁹Zr¹⁷⁷Lu theranostic trial.. Journal of Clinical Oncology, 2019, 37, 261-261.	0.8	5
78	Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology, 2019, 37, 544-544.	0.8	13
79	Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. Journal of Clinical Oncology, 2019, 37, 564-564.	0.8	10
80	Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.. Journal of Clinical Oncology, 2019, 37, 581-581.	0.8	14
81	A potent liver-mediated mechanism for loss of muscle mass during androgen deprivation therapy. Endocrine Connections, 2019, 8, 605-615.	0.8	3
82	Nivolumab in the treatment of advanced renal cell carcinoma. Future Oncology, 2018, 14, 1679-1689.	1.1	3
83	Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer. Scientific Reports, 2018, 8, 1508.	1.6	3
84	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2018, 378, 1277-1290.	13.9	3,334
85	Quantitation of the anticancer drug abiraterone and its metabolite \hat{r} (4)-abiraterone in human plasma using high-resolution mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2018, 154, 66-74.	1.4	23
86	Realâ€world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia. Asia-Pacific Journal of Clinical Oncology, 2018, 14, e45-e49.	0.7	3
87	Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. Journal of Clinical Oncology, 2018, 36, 2639-2646.	0.8	131
88	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. Journal of Clinical Oncology, 2018, 36, 1579-1587.	0.8	97
89	Impact of prognostic factors and risk groups on overall survival (OS) in patients treated with pembrolizumab vs investigatorâ€™s choice chemotherapy for advanced urothelial cancer (UC): Post hoc analysis of KEYNOTE-045. Annals of Oncology, 2018, 29, viii320-viii321.	0.6	3
90	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. British Journal of Cancer, 2018, 119, 663-669.	2.9	66

#	ARTICLE	IF	CITATIONS
91	Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2018, 36, 4511-4511.	0.8	12
92	Pembrolizumab (pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.. Journal of Clinical Oncology, 2018, 36, 4521-4521.	0.8	6
93	A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, 5008-5008.	0.8	8
94	KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS4599-TPS4599.	0.8	16
95	Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2018, 36, 410-410.	0.8	19
96	Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564.. Journal of Clinical Oncology, 2018, 36, TPS712-TPS712.	0.8	5
97	Patterns of care and outcome of germ cell tumours (GCT) in an Australian high-volume centre.. Journal of Clinical Oncology, 2018, 36, e16534-e16534.	0.8	0
98	Cardiovascular toxicity of targeted therapies for cancer: a protocol for an overview of systematic reviews. BMJ Open, 2018, 8, e021064.	0.8	1
99	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine, 2017, 376, 1015-1026.	13.9	2,677
100	Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer. British Journal of Cancer, 2017, 116, 1002-1011.	2.9	48
101	CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. European Urology, 2017, 72, 962-971.	0.9	199
102	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. European Urology, 2017, 72, 368-376.	0.9	209
103	Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group's study. European Journal of Cancer, 2017, 80, 55-62.	1.3	18
104	Cabazitaxel in patients with metastatic castration-resistant prostate cancer: safety and quality of life data from the Australian early access program. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 391-399.	0.7	9
105	e-TC: Development and pilot testing of a web-based intervention to reduce anxiety and depression in survivors of testicular cancer. European Journal of Cancer Care, 2017, 26, e12698.	0.7	25
106	Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival. Cancer Medicine, 2017, 6, 2188-2193.	1.3	25
107	Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. British Journal of Cancer, 2017, 117, 913-920.	2.9	145
108	Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?. Oncologist, 2017, 22, 1470-1477.	1.9	10

#	ARTICLE	IF	CITATIONS
109	Dose considerations for anti-cancer drugs in metastatic prostate cancer. <i>Prostate</i> , 2017, 77, 1199-1204.	1.2	5
110	Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 385-393.	1.1	25
111	Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 31-49.	1.5	52
112	Pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine for recurrent, advanced urothelial cancer (UC): Mature results from the phase 3 KEYNOTE-045 trial. <i>Annals of Oncology</i> , 2017, 28, v623.	0.6	4
113	A distinct plasma lipid signature associated with poor prognosis in castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2017, 141, 2112-2120.	2.3	54
114	Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4501-4501.	0.8	17
115	Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4530-4530.	0.8	6
116	A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5004-5004.	0.8	9
117	Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS4594-TPS4594.	0.8	15
118	Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 282-282.	0.8	6
119	MILGa-01: A first-in-human study assessing the safety and tolerability of chMIL-38 in metastatic prostate, bladder, and pancreatic cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, e565-e565.	0.8	3
120	The plasma lipidome in castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5055-5055.	0.8	0
121	Communicating risk in active surveillance of localised prostate cancer: a protocol for a qualitative study. <i>BMJ Open</i> , 2017, 7, e017372.	0.8	0
122	The effect of pulmonary function testing on bleomycin dosing in germ cell tumours. <i>Internal Medicine Journal</i> , 2016, 46, 893-898.	0.5	14
123	High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 149-159.	1.1	43
124	Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). <i>Annals of Oncology</i> , 2016, 27, 2302-2303.	0.6	1
125	Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—the TADE Study. <i>Clinical Cancer Research</i> , 2016, 22, 3164-3171.	3.2	60
126	Patterns and trends in the incidence of paediatric and adult germ cell tumours in Australia, 1982–2011. <i>Cancer Epidemiology</i> , 2016, 43, 15-21.	0.8	12

#	ARTICLE	IF	CITATIONS
127	The prevalence, severity, and correlates of psychological distress and impaired health-related quality of life following treatment for testicular cancer: a survivorship study. <i>Journal of Cancer Survivorship</i> , 2016, 10, 223-233.	1.5	57
128	Treatment beyond progression with nivolumab (nivo) in patients (pts) with advanced renal cell carcinoma (aRCC) in the phase III CheckMate 025 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4509-4509.	0.8	11
129	Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4557-4557.	0.8	4
130	Phase II trial of circulating cytokines as markers of docetaxel (DTX) resistance in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5039-5039.	0.8	1
131	CheckMate 025 phase III trial: Outcomes by key baseline factors and prior therapy for nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 498-498.	0.8	21
132	Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumors: updated analysis of an Australian multicenter phase II trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16056-e16056.	0.8	0
133	Simplified CYP2D6 metabolizer phenotype categorization of patients treated with tamoxifen: Role for endoxifen level monitoring?. <i>Journal of Clinical Oncology</i> , 2016, 34, 536-536.	0.8	0
134	Positive lifestyle changes following urological cancer diagnoses â€œ an Australian interview based study. <i>International Journal of Human Rights in Healthcare</i> , 2015, 8, 110-119.	0.6	1
135	Doctor-patient communication: a study of Australian ethnic urological cancer patients. <i>International Journal of Human Rights in Healthcare</i> , 2015, 8, 82-91.	0.6	2
136	Clinical perspectives: Practical insights from clinical experience with cabazitaxel in <sc>A</sc>ustralia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2015, 11, 199-207.	0.7	5
137	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1803-1813.	13.9	4,889
138	Tamoxifen (TAM)-induced severe hot flashes (HF): Is dose reduction (DR) a safe and effective strategy?. <i>Journal of Clinical Oncology</i> , 2015, 33, 557-557.	0.8	0
139	Abstract 5493: Genome-wide study of carboplatin and paclitaxel disposition in ovarian cancer patients. , 2015, , .		0
140	Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 81-89.	2.3	67
141	Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). <i>Annals of Oncology</i> , 2014, 25, 143-148.	0.6	31
142	Challenges in the sequencing of therapies for the management of metastatic castrationâ€™resistant prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 205-215.	0.7	6
143	Racial disparity in metastatic renal cell cancer: The pharmacoâ€™anthropology of sunitinib. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 197-199.	0.7	1
144	Predictive Value of CYP3A and ABCB1 Phenotyping Probes for the Pharmacokinetics of Sunitinib: the ClearSun Study. <i>Clinical Pharmacokinetics</i> , 2014, 53, 261-269.	1.6	23

#	ARTICLE	IF	CITATIONS
145	Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2014, 110, 2462-2471.	2.9	122
146	Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. <i>British Journal of Cancer</i> , 2014, 111, 1802-1809.	2.9	77
147	Use of Targeted Therapies for Advanced Renal Cell Carcinoma in the Asia-Pacific Region: Opinion Statement From China, Japan, Taiwan, Korea, and Australia. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 225-233.	0.9	22
148	Effect of toxicity-adjusted dose (TAD) of sunitinib on intra-patient variation of trough levels: A longitudinal study in metastatic renal cell cancer (mRCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 2597-2597.	0.8	3
149	Methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 11-11.	0.8	6
150	Defining the Starting Dose: Should It Be mg/kg, mg/m ² , or Fixed?. <i>Cancer Drug Discovery and Development</i> , 2014, , 69-87.	0.2	1
151	Circulating microRNAs associated with docetaxel-resistant castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 44-44.	0.8	0
152	Genome-wide association study for identification of candidate SNPs associated with carboplatin and paclitaxel clearance in ovarian cancer patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5563-5563.	0.8	0
153	Functional Analysis of Novel Polymorphisms in the Human SLCO1A2 Gene that Encodes the Transporter OATP1A2. <i>AAPS Journal</i> , 2013, 15, 1099-1108.	2.2	41
154	Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. <i>BJU International</i> , 2013, 112, E250-5.	1.3	101
155	Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia. <i>Journal of Translational Medicine</i> , 2013, 11, 189.	1.8	25
156	The prevalence and correlates of supportive care needs in testicular cancer survivors: a cross-sectional study. <i>Psycho-Oncology</i> , 2013, 22, 2557-2564.	1.0	65
157	Factors predicting endoxifen levels in breast cancer patients taking standard-dose tamoxifen and following dose escalation.. <i>Journal of Clinical Oncology</i> , 2013, 31, 543-543.	0.8	26
158	Association analysis of polymorphisms in genes related to sunitinib pharmacokinetics.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4580-4580.	0.8	0
159	Abstract A55: Influence of ABCB1 polymorphisms on paclitaxel pharmacokinetics in ovarian cancer patients. , 2013, , .		0
160	Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies. <i>Journal of Clinical Oncology</i> , 2012, 30, 4017-4025.	0.8	172
161	Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: The Australian perspective. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 31-42.	0.7	4
162	Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and U.K. phase I/II trials.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4531-4531.	0.8	1

#	ARTICLE	IF	CITATIONS
163	<i>CYP2D6</i> genotype and adverse effects as indicators of plasma endoxifen in breast cancer patients taking tamoxifen.. Journal of Clinical Oncology, 2012, 30, 550-550.	0.8	0
164	Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treatment Reviews, 2011, 37, 251-260.	3.4	98
165	Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2. Clinical Pharmacology and Therapeutics, 2011, 89, 816-820.	2.3	53
166	Paraneoplastic Hepatic Dysfunction in Metastatic Prostate Cancer: The Role of Cytokine Dysregulation. Journal of Clinical Oncology, 2011, 29, e21-e23.	0.8	12
167	Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian cancer. British Journal of Cancer, 2011, 105, 360-365.	2.9	28
168	Metformin in prostate cancer: two for the price of one. Annals of Oncology, 2011, 22, 2556-2560.	0.6	61
169	Abstract 4679: A multi-stage genome-wide association study on response to chemotherapy in ovarian cancer. , 2011, , .		0
170	Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. British Journal of Clinical Pharmacology, 2010, 69, 484-497.	1.1	66
171	Comparison of Two Standard Chemotherapy Regimens for Good-Prognosis Germ Cell Tumors: Updated Analysis of a Randomized Trial. Journal of the National Cancer Institute, 2010, 102, 1253-1262.	3.0	64
172	Inhibitors of mTOR. Oncologist, 2010, 15, 1262-1269.	1.9	60
173	Irinogenetics: How Many Stars Are There in the Sky?. Journal of Clinical Oncology, 2009, 27, 2578-2579.	0.8	13
174	An Open-Label, Single-Arm Phase Two Trial of Gefitinib in Patients With Advanced or Metastatic Castration-Resistant Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 338-341.	0.6	46
175	Outcomes and predicting response in anaemic chemotherapy patients treated with epoetin alfa. A multicentre, 4-month, open-label study in Australia and New Zealand. Internal Medicine Journal, 2008, 38, 751-757.	0.5	6
176	Multinodular goitre: an unusual cause in a patient with acromegaly. Internal Medicine Journal, 2008, 38, 742-743.	0.5	1
177	Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer: An effect of improved systemic therapy?. Journal of Medical Imaging and Radiation Oncology, 2008, 52, 376-381.	0.9	23
178	Dose calculation of anticancer drugs. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 1307-1319.	1.5	35
179	Transporter pumps and imatinib: A cause of pharmacokinetic resistance?. Cancer Biology and Therapy, 2008, 7, 416-418.	1.5	1
180	Obesity in Dose Calculation: A Mouse or an Elephant?. Journal of Clinical Oncology, 2007, 25, 4703-4704.	0.8	17

#	ARTICLE	IF	CITATIONS
181	Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 82, 33-40.	2.3	135
182	Allogeneic bone marrow transplant for refractory mediastinal germ cell tumour: possible evidence of graft-versus-tumour effect. <i>Internal Medicine Journal</i> , 2007, 37, 127-129.	0.5	2
183	Death of a clinical trial: a speculative inclusion criterion gone wrong. <i>Internal Medicine Journal</i> , 2007, 37, 838-839.	0.5	0
184	Sunitinib malate in the treatment of renal cell carcinoma and gastrointestinal stromal tumor: Recommendations for patient management*. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2007, 3, 167-176.	0.7	14
185	Developing a New Framework for Dose Calculation. <i>Journal of Clinical Oncology</i> , 2006, 24, 1489-1490.	0.8	19
186	Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. <i>European Journal of Cancer</i> , 2006, 42, 1083-1092.	1.3	107
187	Maintaining bone health in patients with prostate cancer. <i>Medical Journal of Australia</i> , 2006, 184, 176-179.	0.8	24
188	Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 2448-2455.	0.8	58
189	Hepatic technetium Tc 99m ^{99m} -labeled sestamibi elimination rate and () genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 33-42.	2.3	52
190	I don't underdose my patientsâ€¦do I?. <i>Lancet Oncology</i> , The, 2005, 6, 637-638.	5.1	24
191	CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy*1. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 529-538.	2.3	86
192	Defining the Starting Dose. , 2004, , 57-73.		3
193	Phase II trial of branched peginterferon-Î± 2a (40 kDa) for patients with advanced renal cell carcinoma. <i>Annals of Oncology</i> , 2002, 13, 1799-1805.	0.6	46
194	How to calculate the dose of chemotherapy. <i>British Journal of Cancer</i> , 2002, 86, 1297-1302.	2.9	212
195	Î±-Interferon 2a and 13-cis-retinoic acid for the treatment of metastatic renal cell carcinoma. <i>Internal Medicine Journal</i> , 2002, 32, 158-162.	0.5	6
196	Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: Effective treatment of patients with poor prognostic features. <i>Annals of Oncology</i> , 2001, 12, 947-952.	0.6	49
197	A phase II trial of paclitaxel and epirubicin in advanced breast cancer. <i>British Journal of Cancer</i> , 2000, 83, 438-442.	2.9	15
198	Home or Hospital? An Evaluation of the Costs, Preferences, and Outcomes of Domiciliary Chemotherapy. <i>International Journal of Health Services</i> , 2000, 30, 557-579.	1.2	49

#	ARTICLE	IF	CITATIONS
199	Initial Paclitaxel Improves Outcome Compared With CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 1999, 17, 2355-2355.	0.8	206
200	Long-Term Follow-Up of Patients Treated with Intermittent Hormone Therapy for Advanced Prostate Cancer. <i>Prostate Journal</i> , 1999, 1, 138-143.	0.2	2
201	Inflammatory breast cancer: enhanced local control with hyperfractionated radiotherapy and incisional vincristine, ifosfamide and epirubicin. <i>Australian and New Zealand Journal of Medicine</i> , 1998, 28, 400-402.	0.5	8
202	Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation.. <i>Journal of Clinical Oncology</i> , 1998, 16, 2299-2304.	0.8	116
203	Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.. <i>Journal of Clinical Oncology</i> , 1996, 14, 2590-2611.	0.8	329
204	Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer. <i>European Journal of Cancer</i> , 1995, 31, 1773-1777.	1.3	5
205	Hypercalcaemia in small cell lung cancer: Report of a case associated with parathyroid hormone-related protein (PTHrP). <i>European Journal of Cancer</i> , 1993, 29, 1601-1604.	1.3	5
206	Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. <i>Lancet</i> , The, 1993, 341, 1611-1613.	6.3	91
207	Escalating drug delivery in cancer chemotherapy: A review of concepts and practice "Part 2. <i>Annals of Oncology</i> , 1993, 4, 103-115.	0.6	38
208	A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. <i>Medical Journal of Australia</i> , 1993, 158, 319-322.	0.8	37
209	A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma. <i>Medical Journal of Australia</i> , 1993, 158, 866-866.	0.8	0
210	Infection risk in patients with small cell lung cancer receiving intensive chemotherapy and recombinant human granulocyte-macrophage colony-stimulating factor. <i>European Journal of Cancer</i> , 1992, 28, 105-112.	1.3	18
211	Haemopoietic cell kinetics in humans treated with rGM-CSF. <i>International Journal of Cancer</i> , 1992, 50, 26-31.	2.3	63
212	Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer. <i>European Journal of Cancer & Clinical Oncology</i> , 1991, 27, 565-567.	0.9	10
213	The Use of L-dopa and Carbidopa in Metastatic Malignant Melanoma. <i>Journal of Investigative Dermatology</i> , 1991, 96, 85-87.	0.3	20
214	A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 142-144.	1.1	4
215	The management of primary fallopian tube carcinoma. <i>BJOC: an International Journal of Obstetrics and Gynaecology</i> , 1990, 97, 822-826.	1.1	13
216	Dose intensity in cancer chemotherapy. <i>British Journal of Cancer</i> , 1990, 61, 789-794.	2.9	42

#	ARTICLE	IF	CITATIONS
217	Bone metastases in hypernephroma. Frequency of scapular involvement. Cancer, 1989, 64, 1429-1431.	2.0	12
218	RENAL PHOSPHATE THRESHOLD AND RESPONSE TO PAMIDRONATE IN HUMORAL HYPERCALCAEMIA OF MALIGNANCY. Lancet, The, 1989, 334, 241-244.	6.3	34
219	A second australian family with hemoglobin north shore ($\hat{\text{I}}^{2134}\text{VAL}\hat{\text{A}}\text{T}\hat{\text{I}}\text{GLU}$). Pathology, 1987, 19, 62-63.	0.3	1